NewsSource: EClinCloud Official Website Archive

Regulatory Brief | Neuropathic Pain Clinical Trials to Receive Formal Technical Guidance

2 min readEClinCloud Editorial Team
Regulatory Update | Formal Technical Guidance Forthcoming for Neuropathic Pain Clinical Trials (archived article cover)

On September 8, 2025, the Center for Drug Evaluation (CDE) issued a notice seeking public comment on the "Technical Guidelines for Clinical Trials of Drugs for Neuropathic Pain (Draft for Comment)." This marks an initial effort in China to issue systematic guidance in this field.

CDE神经病理性疼痛药物临床试验指导原则征求意见通知  

 

Background

Neuropathic pain (NP) is chronic pain caused by a lesion or disease affecting the somatosensory nervous system, often manifesting as burning pain or electric-shock-like pain and severely affecting patients' quality of life.

Domestic and international developments: The United States and Europe have successively issued relevant development guidelines, and several new drugs have been approved; clinical need in China is urgent, yet systematic guidance documents were previously lacking.

Purpose of issuance: To improve R&D efficiency and quality by establishing technical guidelines, and in particular to provide reference recommendations on Phase III clinical trial design elements.

 

 

Interpretation of key points

1. R&D Principles

Guided by clinical needs, ensure that drug development meets the core objective of benefit-risk assessment.

Full drug lifecycle management is encouraged, including indication expansion, formulation optimization, etc.

 

2. Key Design Elements for Phase III Trials

Overall trial design: randomized, double-blind, placebo-controlled for ≥12 weeks; peripheral NP (PHN, DPNP) and central NP must be confirmed separately.

Inclusion and exclusion criteria: Trial participants must have a pain duration of ≥3 months and a pain score of at least moderate severity (VAS ≥40 mm or NRS ≥4 points).

Efficacy endpoints: The core endpoint is the weekly average daily pain score (ADPS), while multidimensional scales and scales assessing concomitant symptoms and quality of life should also be included.

Multidimensional pain scales: for example, the Short-Form McGill Pain Questionnaire (SF-MPQ), Neuropathic Pain Scale (NPS), and Neuropathic Pain Symptom Inventory (NPSI);

Concomitant symptom and quality-of-life scales: sleep interference (ADSIS, MOS-SS), emotional state (HADS), quality of life (SF-36, EQ-5D-5L), and Patient Global Impression of Change (PGIC).

Safety requirements: focus on central nervous system side effects and abuse risk; compliance with ICH E1 long-term exposure requirements is required.

 

3. Other considerations

Data extrapolation: dose exploration can be extrapolated across different disease models.

Active control: pregabalin may be considered as a reference drug.

Special populations: Trials in older adults need to consider age-friendly design; research evidence in pediatric populations is limited, and exploration is recommended starting from ≥12 years of age.

 

 

As can also be seen from this document, scales are at the core of the evaluation system for neuropathic pain clinical trials, and using scientific, rigorous, and standardized scale instruments can safeguard the reliability of trial data.

EClinCloud has accumulated extensive scale-service experience across multiple therapeutic areas, including pain and CNS, providing one-stop services covering scales, rater training, and eCOA systems to deliver scientific, professional support for sponsor study scale selection and rater training. Inquiries are welcome.

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.